Status of the Bundibugyo Ebola Outbreak and Response in the DRC

• Bundibugyo Ebola cases in the Democratic Republic of Congo (DRC) have surpassed 1,000, with no licensed vaccine or treatment currently available.
• The fatality rate for this strain is estimated between 30% and 40%, lower than the Zaire strain but harder to detect early due to subtle symptoms.
• Efforts are focused on public health interventions to break chains of transmission while exploring potential therapeutic molecules.

Bundibugyo Strain Characteristics

• First identified in Uganda in 2007; previously caused a major outbreak in Isiro, DRC, in 2012.
• Known for less severe bleeding symptoms, which delayed initial detection of the current epidemic.

Vaccine and Treatment Research

• WHO is coordinating groups to test existing molecules in the field as potential treatments.
• The National Institute of Biomedical Research (INRB), co-creators of the 'Ebanga' (monoclonal antibody 114) for the Zaire strain, is working with U.S. partners to develop an antibody specific to the Bundibugyo virus.

Ground Response Strategy

• In the absence of vaccines, officials are relying on proven public health protocols:
  • Rapid identification and isolation of sick individuals.
  • Enhanced safety protocols for hospital staff, including personal protective equipment.
  • Ensuring dignified, safe burials to prevent community spread and build public trust.

Logistics and Funding Challenges

• Security instability in affected provinces remains the primary barrier to an effective healthcare response.
• The response requires significant logistical support, including helicopters and vehicles, which are costly and difficult to mobilize in remote, mountainous areas.
• While international funding has fluctuated, the DRC government has allocated significant national funds, supported by the WHO, Africa CDC, UNICEF, MSF, and ALIMA.